

TABLE S2. Antineoplastic Therapy Since Discontinuation of Ceritinib (FAS)

ATC class	N = 124
	n (%)
Any ATC class	58 (46.8)
Protein kinase inhibitors	46 (37.1)
Preferred term	
Crizotinib	18 (14.5)
Ceritinib	15 (12.1)
Alectinib	10 (8.1)
Lorlatinib	5 (4.0)
Alectinib hydrochloride	4 (3.2)
Brigatinib	2 (1.6)
Erlotinib hydrochloride	2 (1.6)
Gefitinib	1 (0.8)
Investigational drug	10 (8.1)
Folic acid analogues	9 (7.3)
Taxanes	8 (6.5)
Monoclonal antibodies	7 (5.6)
Platinum compounds	4 (3.2)
Vinca alkaloids and analogues	4 (3.2)
Pyrimidine analogues	3 (2.4)
Anthracyclines and related substances	1 (0.8)
Nitrosoureas	1 (0.8)

Abbreviations: ATC, Anatomical Therapeutic Chemical; FAS, full analysis set.